Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7713999 | XSPIRE PHARMA | Thrombin receptor antagonists |
May, 2024
(11 months from now) | |
US7304078 | XSPIRE PHARMA | Thrombin receptor antagonists |
Dec, 2027
(4 years from now) |
Drugs and Companies using VORAPAXAR SULFATE ingredient
Market Authorisation Date: 08 May, 2014
Treatment: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad); Reduction of thrombotic cardiovascular events
Dosage: TABLET;ORAL
18
United States
12
European Union
8
Japan
6
Australia
6
Korea, Republic of
6
Norway
6
China
5
Canada
5
Spain
5
Russia
5
Hong Kong
5
Argentina
5
Brazil
5
South Africa
5
Taiwan
4
Ecuador
4
Israel
4
New Zealand
4
Peru
4
Malaysia
4
Austria
4
Mexico
4
Germany
3
Denmark
3
Cyprus
3
Portugal
3
Slovenia
2
Singapore
2
Poland
1
Colombia
1
Luxembourg
1
Netherlands
1
Chile
1
Slovakia
1
Czech Republic
1
Hungary
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic